Shares of Palvella Therapeutics (NASDAQ: PVLA) surged 15% Tuesday after the company reported positive topline results from its Phase 3 SELVA clinical trial evaluating QTORIN(TM) 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations (mLM). The late-stage study not only met its primary endpoint but also delivered statistically robust results across key secondary measures.

Phase 3 Trial Meets Primary and Secondary Endpoints

The SELVA trial achieved its primary endpoint, demonstrating a statistically significant improvement on the Microcystic Lymphatic Malformation Investigator Global Assessment (mLM-IGA). Participants recorded a mean improvement of +2.13 points (p<0.0001), signaling meaningful clinical benefit.

In addition, the study met its key secondary endpoint on the blinded mLM Multi-Component Static Scale, where patients experienced a mean improvement of 3.36 points (p<0.0001). These outcomes reinforce the therapy's potential efficacy profile in treating a condition with limited targeted options.

Strong Response Rates Across Participants

The Phase 3 study enrolled 51 participants aged three and older across specialized U.S. vascular anomaly centers, with 50 initiating treatment. Among the 49 participants aged six and older who completed the 24-week efficacy evaluation period, 95% showed improvement on the mLM-IGA scale.

Notably, 86% of those patients were classified as either "Much Improved" or "Very Much Improved," underscoring the consistency and magnitude of response observed during the trial.

Favorable Safety and Tolerability Profile

Beyond efficacy, QTORIN(TM) rapamycin demonstrated a strong safety profile. Investigators reported no drug-related serious adverse events, and systemic rapamycin levels remained below 2 ng/mL at all measured timepoints.

Moreover, patient retention remained exceptionally high. Of those who completed the initial evaluation period, 98% opted to continue into the ongoing extension phase, suggesting both tolerability and perceived benefit.

Regulatory Pathway and Market Opportunity

Building on these results, Palvella plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration in the second half of 2026. If approved, QTORIN(TM) rapamycin could become the first therapy specifically indicated for microcystic lymphatic malformations.

The therapy has already received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the FDA, accelerating its development pathway and highlighting its potential clinical importance. Microcystic lymphatic malformations affect an estimated 30,000 individuals in the United States, representing a meaningful unmet medical need within the rare disease landscape.

Investor and Clinical Implications

The strong Phase 3 data significantly de-risks Palvella's development program and strengthens its regulatory outlook. Consequently, the market reacted positively, driving a sharp rally in PVLA shares.

More broadly, the results position Palvella as a potential first-mover in a niche but underserved therapeutic category. For investors, the combination of compelling efficacy data, regulatory momentum, and a defined patient population may support continued interest as the company advances toward NDA submission.

The post Palvella Therapeutics Stock Jumps 15% After Positive Phase 3 Data for QTORIN(TM) appeared first on PRISM MarketView.

COMTEX_474141687/2927/2026-02-24T08:29:21